Recombinant Human CEACAM5 protein (C-hIGg2fc)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
hIGg2fc Tag
Activity
not tested
Cat no : Eg0247
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <1.0 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human CEACAM5 protein Lys35-Ala685 (Accession# BC034671) with a hIGg2fc tag at the C-terminus. |
| GeneID | 1048 |
| Accession | BC034671 |
| PredictedSize | 98.4 kDa |
| SDS-PAGE | |
| Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
CEACAM5 is a cell surface glycoprotein that is overexpressed in a variety of human tumors, including pancreatic cancers, breast cancers, lung cancer, and neuro-endocrine prostate cancer (NEPC) and has been functionally associated with tumor differentiation, invasion, and metastasis. Currently, CEACAM5 has been targeted for developing immunotherapies such as bispecific T cell engagers (BiTEs), CAR-T cells, or ADCs.
References:
1. Han, Zi-Wen et al. Investigational new drugs vol. 38,6 (2020): 1888-1898. 2. DeLucia, Diana C et al. Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,3 (2021): 759-774. 3. Kim, Ye-Jin et al. Frontiers in oncology vol. 13 1124039.